## CVS: CVS Health Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($73.96)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 1)

**1. CVS: JP Morgan Raises Price Target and Maintains Overweight Rati**
- Source: GuruFocus | 20251217T195040 | Bullish | Relevance: 100%
- JP Morgan has raised its price target for CVS Health (CVS) to $101.00 from $93.00, reiterating an "Overweight" rating. This optimistic outlook is consistent with other recent analyst upgrades from firms like Bernstein, Baird, Morgan Stanley, Mizuho, and Barclays, all of whom have increased their price targets for the healthcare company. The average Wall Street target price for CVS is now $93.34, implying a potential upside of 20.47% from its current price.

**2. Has the CVS Stock Surge in 2025 Already Priced In Its Cash Flow Potential?**
- Source: Simply Wall Street | 20251217T153644 | Bullish | Relevance: 100%
- CVS Health (CVS) has seen a significant stock surge of 77.0% year-to-date, prompting a re-evaluation of its potential. Despite this rapid increase, Discounted Cash Flow (DCF) analysis and Price-to-Sales (P/S) ratios suggest the stock remains undervalued by 65.2% and materially undervalued, respectively. The article explores how differing investor narratives, influenced by factors like Medicare Advantage recovery or regulatory risks, can lead to varied intrinsic valuations for CVS.

**3. JPMorgan Chase & Co. Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price**
- Source: MarketBeat | 20251217T150744 | Bullish | Relevance: 100%
- JPMorgan Chase & Co. has raised its price target for CVS Health (NYSE:CVS) to $101 from $93, maintaining an "overweight" rating and suggesting a 29.77% upside. This positive outlook is supported by several other brokers increasing their targets, leading to a consensus "Moderate Buy" rating and a price target of $94.67 for CVS Health. The company recently surpassed quarterly earnings estimates and issued strong FY2025 guidance.

**4. Texas Permanent School Fund Corp Decreases Stake in CVS Health Corporation $CVS**
- Source: MarketBeat | 20251217T110402 | Neutral | Relevance: 100%
- Texas Permanent School Fund Corp significantly reduced its holdings in CVS Health Corporation by 42.9% in the second quarter, selling over 66,000 shares. Despite this, other institutional investors like Osaic Holdings Inc. and Orion Portfolio Solutions LLC increased their stakes. CVS Health reported strong Q3 earnings, exceeding consensus estimates, and analysts currently have a "Moderate Buy" rating with a consensus price target of $93.71 for the company.

**5. Park National Corp OH Has $13.01 Million Holdings in CVS Health Corporation $CVS**
- Source: MarketBeat | 20251216T123416 | Bullish | Relevance: 100%
- Park National Corp OH reduced its stake in CVS Health Corporation by 8.9%, holding 172,605 shares valued at $13.01 million. Despite this, CVS Health reported strong quarterly results, beating EPS and revenue estimates, and received a "Moderate Buy" consensus rating from analysts with a $93.71 price target. The company also declared a quarterly dividend of $0.665.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 10, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | JP Morgan | $101 | $93 | +9% |
| 2025-12-12 | Bernstein | $87 | $86 | +1% |
| 2025-12-10 | Truist Securiti | $98 | $95 | +3% |
| 2025-12-10 | Piper Sandler | $101 | $99 | +2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | JP Morgan | main | Overweight |
| 2025-12-12 | Bernstein | main | Market Perform |
| 2025-12-10 | Truist Securiti | main | Buy |
| 2025-12-10 | Piper Sandler | reit | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 11 ($1.40M) |
| Sells | 4 ($2.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 9.4% (-2.3%)
- Vanguard Group Inc: 9.4% (-1.3%)
- Dodge & Cox Inc.: 5.8% (-0.1%)
- JPMORGAN CHASE & CO: 5.6% (+162.5%)
- Capital World Invest: 5.4% (+2.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 10 raises (avg +6%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.56 indicates undervaluation relative to growth. Analyst sentiment positive (10 raises, avg +6%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $98.7B |
| Beta | 0.48 |
| 52W Range | $43.56 - $85.15 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.56 |
| Forward P/E | 10.9 |
| Current P/E | 11.7 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.3% to 0.6% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.4pp (needs >3.0% for momentum thesis). MRS_5 (-1.0%) diverging from MRS_10 - short-term weakness emerging. Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). RSI neutral at 48. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.57% (CS: 44) | Neutral |
| RSI_14 | 48.1 | Neutral |
| MACD Histogram | 0.04 | Bullish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 0.985x | Below |
| vs SMA200 | 1.106x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.80
- **Stop Loss:** $73.96 (4.9% risk)
- **Target:** $81.64 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 247
- **Position Value:** $19,216.60
- **Portfolio %:** 19.22%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-11 (Est: $0.96)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.36 | $1.60 | +17.9% |
| 2025Q2 | $1.46 | $1.81 | +23.8% |
| 2025Q1 | $1.67 | $2.25 | +34.5% |
| 2024Q4 | $0.92 | $1.19 | +29.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*